Source: China – South China Morning PostA pair of Hong Kong-listed mainland Chinese biotechnology firms are poised to turn a profit this year as their revenue from novel drugs finally outstrips costs related to research and development and marketing, according to analysts.
“Chinese biotechs have matured significantly and are creating value for Chinese patients and government payers,” said Tony Ren, head of Asia healthcare research at Macquarie Capital, in a report on July 16. “[Some will] likely turn profitable soon and no longer rely…Read More